 AIM ImmunoTech Inc NYSE:AIM said its clinical development collaborator Roswell Park Comprehensive Cancer Center has commenced patient enrollment in its phase 2 study evaluating Ampligen rintatolimod in subjects with primary PD-1PD-L1 resistant melanoma. The company said the study, which is funded by the National Cancer Institute NCI, will evaluate type-1 polarized dendritic cell αDC1 vaccine in combination with tumor-selective chemokine modulation comprised of Interferon alpha 2b, Ampligen, and Celecoxib. 